StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$47.29−3.73 (-7.31%)

Close on Nov 17, 2026Market cap $1.41BP/E –Yield –

GeneDx price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

GeneDx's price to sales ratio was 3.6× on Nov 10, 2026, against 12.0× a year earlier. Over the last 5 years it ranged from 0.0× to 12.0×, with a median of 3.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 10, 20263.6×−5.7
2025Dec 31, 20259.3×+1.5
2024Dec 31, 20247.9×+7.5
2023Dec 29, 20230.3×−0.1
2022Dec 30, 20220.4×+0.4
2021Jan 29, 20210.0×+0.0
2020Dec 31, 20200.0×–

More GeneDx figures

See a number that looks wrong?